SCHEMBL4714263

SCHEMBL4714263

COC(=O)c1n[nH]c(N)c1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.49
KDM4E B2RXH2 3/20 0.44
STAT3 P40763 1/20 0.44
HIF1A Q16665 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
TSHR P16473 1/20 0.43
ALDH1A1 P00352 5/20 0.38
GAA P10253 2/20 0.38
GFER P55789 2/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 2/20 0.33
F2 P00734 2/20 0.33
HPGD P15428 1/20 0.33
TP53 P04637 1/20 0.33
LMNA P02545 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
FLT3 P36888 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1009945 0.81 KDM4C (0.52) KDM4CKDM4ESTAT3HIF1ANPSR1
SCHEMBL11089588 0.79 KDM4C (0.50) KDM4CKDM4ESTAT3HIF1ANPSR1
SCHEMBL14857837 0.79 KDM4C (0.50) KDM4CKDM4ESTAT3HIF1ANPSR1
SCHEMBL23305772 0.79 KDM4C (0.50) KDM4CKDM4ESTAT3HIF1ANPSR1
SCHEMBL29749406 0.79 KDM4C (0.65) KDM4CKDM4ESTAT3HIF1ANPSR1
SCHEMBL22424292 0.78 KDM4C (0.49) KDM4CKDM4ESTAT3HIF1ANPSR1
SCHEMBL26910743 0.75 KDM4C (0.46) KDM4CKDM4ESTAT3HIF1ANPSR1
SCHEMBL28835653 0.75 HCAR2 (0.47) KDM4CKDM4ESTAT3HIF1ANPSR1
SCHEMBL26910771 0.74 KDM4C (0.41) KDM4CKDM4ESTAT3HIF1ANPSR1
SCHEMBL6993979 0.72 KDM4C (0.65) KDM4CKDM4ESTAT3HIF1ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1877401-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM Elan Pharmaceuticals Inc. (US) 2008-01-16 EP disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
WO-2006113140-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM ELAN PHARMACEUTICALS, INC. (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism BDKRB1, BDKRB2, NPBWR1 KDM4C 4666/4885KDM4E 4606/4885STAT3 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.